Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3

dc.contributor.authorGiménez Llort, Lydia
dc.contributor.authorSantana-Santana, Mikel
dc.contributor.authorRatia, Míriam
dc.contributor.authorPérez, Belén
dc.contributor.authorCamps García, Pelayo
dc.contributor.authorMuñoz-Torrero López-Ibarra, Diego
dc.contributor.authorBadía, A. (Albert)
dc.contributor.authorClos, Victòria
dc.date.accessioned2021-04-29T10:48:57Z
dc.date.available2021-04-29T10:48:57Z
dc.date.issued2021
dc.date.updated2021-04-29T10:48:57Z
dc.description.abstractA new hypothesis highlights sleep-dependent learning/memory consolidation and regards the sleep-wake cycle as a modulator of beta-amyloid and tau Alzheimer's disease (AD) pathologies. Sundowning behavior is a common neuropsychiatric symptom (NPS) associated with dementia. Sleep fragmentation resulting from disturbances in sleep and circadian rhythms in AD may have important consequences on memory processes and exacerbate the other AD-NPS. The present work studied the effect of training time schedules on 12-month-old male 3xTg-AD mice modeling advanced disease stages. Their performance in two paradigms of the Morris water maze for spatial-reference and visual-perceptual learning and memory were found impaired at midday, after 4 h of non-active phase. In contrast, early-morning trained littermates, slowing down from their active phase, exhibited better performance and used goal-directed strategies and non-search navigation described for normal aging. The novel multitarget anticholinesterasic compound AVCRI104P3 (0.6 umol/kg, 21 days i.p.) exerted stronger cognitive benefits than its in vitro equipotent dose of AChEI huprine X (0.12 umol/kg, 21 days i.p.). Both compounds showed streamlined drug effectiveness, independently of the schedule. Their effects on anxiety-like behaviors were moderate. The results open a question of how time schedules modulate the capacity to respond to task demands and to assess/elucidate new drug effectiveness.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec711580
dc.identifier.issn2076-3425
dc.identifier.pmid33810622
dc.identifier.urihttps://hdl.handle.net/2445/176894
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/brainsci11040426
dc.relation.ispartofBrain Sciences, 2021, vol. 11, num. 4, p. 426
dc.relation.urihttps://doi.org/10.3390/brainsci11040426
dc.rightscc-by (c) Giménez Llort, Lydia et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationRitmes circadiaris
dc.subject.classificationEnvelliment
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.otherCircadian rhythms
dc.subject.otherAging
dc.subject.otherAlzheimer's disease
dc.titleClock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
711580.pdf
Mida:
738.71 KB
Format:
Adobe Portable Document Format